Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Home Use On-Body Delivery System for Ocrevus in Multiple Sclerosis
2025-523726-40-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Successful self/lay caregiver administration of Week 1 dose. Planned start Jun 2026; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-523726-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523726-40-00.